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Dawn Sheppard, Christopher Bredeson, David Allan, Jason TayCollection of adequate hematopoietic stem cells (HSCs) is necessary for successful autologous transplanta-
tion; however, a proportion of patients fail to collect the minimum number of cells required.We summarized
the efficacy and safety of HSC mobilization strategies. We performed a systematic review of randomized
controlled trials comparing HSC mobilization strategies before autologous transplantation for hematologic
malignancies. The primary outcome was CD341 cell yield. Secondary outcomes included number of apher-
eses, proportion of failures, rate of count recovery, and adverse events. We identified 28 articles within 3
broad strategies. Using a cyclophosphamide with growth factor strategy (10 articles), CD341 cell yield is
improved by addition of molgramostim to cyclophosphamide (1.4 vs 0.5  106/kg; P 5 .0165), addition of
cyclophosphamide to filgrastim (7.2 vs 2.5 106/kg; P5.004), and addition of ancestim to cyclophosphamide
and filgrastim (12.4 vs 8.3  106/kg; P5 .007). Within a growth factor-based strategy (6 articles), addition of
plerixafor improves CD341 cell yield over filgrastim alone in multiple myeloma (MM; 11.0 vs 6.2  106/kg;
P \ .001) and non-Hodgkin lymphoma (5.69 vs 1.98  106/kg; P \ .01). With combination or
noncyclophosphamide-based chemotherapy (12 articles), higher-dose filgrastim (8.2 vs 4.7  106/kg for
16 vs 8/mcg/kg daily of filgrastim, respectively; P\.0001) and addition of rituximab to etoposide and filgras-
tim (9.9 vs 5.6  106/kg; P5 .021) improve CD341 cell yield. Growth factor alone after chemotherapy, an-
cestim, or plerixafor provide adequate autologous HSC grafts for the majority of patients. Although some
strategies result in higher CD341 cell yield, this potentially comes at the expense of increased toxicity.
As all strategies are reasonable, programmatic, and patient-specific considerations must inform the approach
to autologous graft mobilization.
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PlerixaforINTRODUCTION
High-dose chemotherapy, supported by autologous
hematopoietic stem cell transplantation (HSCT), is an
effective treatment strategy for a variety of hemato-
logic malignancies [1-4]. The collection of adequate
numbers of HSCs is a prerequisite for proceeding to
autologous transplantation; however, approximatelyOttawa Hospital Research Institute, Ottawa Hospital
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6/j.bbmt.2012.01.0085% to 40% of patients do not meet the minimum
threshold of 2  106 CD341 cells/kg that is associated
with timely engraftment [5-9]. Although mobilized
peripheral blood is preferred over bone marrow as the
cell source for autologous transplantation [10], the opti-
mal mobilization regimen for procurement of autolo-
gous HSCs remains unknown.
A variety of mobilization strategies are currently
used, including growth factors alone or in combination
with chemotherapy and, more recently, the partial
CXC chemokine receptor-4 (CXCR-4) agonist,
plerixafor.Of the availablegrowth factors, themost com-
monly used is the recombinant granulocyte-colony stim-
ulating factor (G-CSF) analog, filgrastim [11]. Other
growth factors include pegfilgrastim, a polyethylene
glycol conjugate of G-CSF; lenograstim, glycosylated
recombinant G-CSF; molgramostim, recombinant
granulocyte macrophage colony-stimulating factor;
sargramostim, glycosylated granulocyte macrophage1191
Table 1. MEDLINE Search Strategy
1. Hematopoietic Stem Cell Mobilization/(2615)
2. (stem cell$ adj3 mobil$).tw. (1732)
3. (hsc$ adj3 mobil$).tw. (135)
4. (bone marrow adj3 mobil$).tw. (579)
5. (Hematopoietic adj3 Mobil$).tw. (557)
6. (progenitor cell$ adj3 mobil$).tw. (1024)
7. (mobilisation or mobilization).tw. (34442)
8. or/1-7 (36567)
9. (plerixafor or amd3100 or amd 3100 or jm 3100 or jm3100).af.
(536)
10. mozobil.af. (11)
11. exp Granulocyte Colony-Stimulating Factor/(11370)
12. exp Granulocyte-Macrophage Colony-Stimulating Factor/(12702)
13. (GCSF or G-CSF or GMCSF or G-MCSF).tw. (10430)
14. hematopoietic cell growth factors/or stem cell factor/(4837)
15. Cyclophosphamide/(39369)
16. exp Antineoplastic Agents/(683920)
17. Antineoplastic Combined Chemotherapy Protocols/(83778)
18. chemotherap$.tw. (209311)
19. Receptors, CXCR4/ai [Antagonists & Inhibitors] (535)
20. (CXCR4 antagonist$ or CXCR4 inhibitor$).tw. (414)
21. or/9-20 (821399)
22. 8 and 21 (4996)
23. Bone Marrow Transplantation/(37961)
24. exp Stem Cell Transplantation/(36650)
25. (HSCTor bmt or pbpct or sct).tw. (15427)
26. transplant$.tw. (272768)
27. exp Neoplasms, Plasma Cell/(35525)
28. (leukemia$ or myeloma$).tw. (169031)
29. or/23-28 (460564)
30. randomized controlled trial.pt. (294851)
31. controlled clinical trial.pt. (81941)
32. randomized.ab. (249657)
33. placebo.ab. (123384)
34. clinical trials as topic.sh. (149493)
35. randomly.ab. (154634)
36. trial.ti. (89994)
37. or/30-36 (714333)
38. 22 and 29 and 37 (421)
1192 Biol Blood Marrow Transplant 18:1191-1203, 2012D. Sheppard et al.colony-stimulating factor; and ancestim, recombinant
human stem cell factor. Lenograstim is widely used for
HSC mobilization in Europe; sargramostim, molgra-
mostim,andancestimare rarelyused formobilization to-
day.
A combination of chemotherapy along with growth
factor is a commonly used strategy for mobilization.
Chemotherapy is added to improve CD341 cell yield
[12,13], for in vivo purging of mobilized tumor cells
to reduce tumor burden (although there are limited
supportive data), and to show chemosensitivity before
transplantation. However, approximately 30% of
patients undergoing a mobilization strategy that
includes chemotherapy will develop neutropenic fever
[14], and many of those will require hospitalization.
The most commonly used chemotherapy regimens
include cyclophosphamide at a variety of doses, particu-
larly in patients with multiple myeloma (MM) [15,16].
Mobilization regimens for patients with lymphoma
are varied and include ifosphamide, carboplatin, and
etoposide, dexamethasone, doxorubicin, cytarabine,
and cisplatin (DHAP), etoposide, methyl prednisolone,
cytarabine, and cisplatin and others [17,18].
Plerixafor belongs to a new class of small molecules
that reversibly bind to CXCR-4, inhibiting chemokine
stromal cell-derived factor-1a [19-21]. In phase 1 and
2 studies, plerixafor either alone or in combination
with G-CSF, significantly increased the number of
CD341 cells collected [22,23]. In a phase 2 study of
patients with MM and non-Hodgkin lymphoma
(NHL), the addition of plerixafor to G-CSF increased
the likelihood of collection of at least 5  106 CD341
cells/kg and allowed collection to be completed in
fewer aphereses [22]. In these studies, plerixafor was
well tolerated.
The optimal type and dose of growth factor-based
mobilization is notwell defined.Similarly, it is unknown
whether the potential benefits of chemotherapy-based
mobilizationmay be offset by an increased risk of infec-
tious complications. Finally, the role of plerixafor has
not been clearly delineated. Herein, we summarize,
within the context of a systematic review of randomized
controlled trials (RCTs), the relative efficacy and safety
of different HSC mobilization strategies in patients
undergoing autologous HSCT for hematologic malig-
nancies. Considerations for programs when selecting
a mobilization strategy are also discussed.METHODS
A systematic literature search was performed
using Ovid MEDLINE (1950 to week 42 of 2010),
EMBASE (1980 to week 42 of 2010), and all EBM re-
views (1950 to the fourth quarter of 2010) using the
search strategy detailed in Table 1. Further, references
were reviewed to identify any additional studies.Our primary outcome was median CD341 cell
yield. Secondary efficacy outcomes included median
number of aphereses required to collect the minimum
HSC yield, proportion of patients going on to trans-
plantation, proportion of patients in whom there was
failure to collect theminimumCD341 cell yield as de-
fined by the study, and for those proceeding to HSCT,
time to neutrophil recovery, and platelet recovery.
Secondary safety outcomes included a measure of the
extent of febrile neutropenia and hospital or intensive
care unit admissions.
Using an explicit statement of questions with re-
spect to participants, interventions, comparisons, out-
comes, and study design [24], studies that met the
following inclusion criteria were included in our re-
view: (1) included patients .18 years undergoing
peripheral bloodHSC collection for autologous trans-
plantation, (2) compared at least 2 mobilization strate-
gies using a randomized controlled study design, and
(3) measured at least 1 of our study outcomes. Pub-
lished studies in all languages were included. We
excluded unpublished studies, studies published in ab-
stract form only, nonrandomized, quasi randomized,
or crossover studies, studies involving animals, and
Figure 1. Flow diagram summarizing the identification process of relevant clinical trials.
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tions: mobilization of donor HSCs before allogeneic
transplantation, mobilization before autologous trans-
plantation for solid tumors, and mobilization before
bone marrow harvest.
Two reviewers (D.S. and J.T.) independently ap-
plied the inclusion and exclusion criteria to the articles
identified by the search strategy and extracted the data
using a standardized data abstraction form. Full text
articles assessed for inclusion were discussed between
the 2 reviewers. Trial quality was assessed using a vali-
dated 5-point system as proposed by Jadad et al. [25]. A
Jadad score of 3 or higher was considered high quality.
Trial quality was further assessed with the use of stan-
dardized questions related to methodology, such as al-
location concealment [26]. Trial quality was judged
conservatively such that if an item (eg, the appropriate-
ness of the randomization method) was not reported, it
was negatively scored.RESULTS
The systematic search strategy identified a total
of 1,039 articles. Eighty duplicate articles were ex-
cluded, and the remaining 959 were screened for rel-
evance based on their titles or abstracts. Of these, 34
were deemed potentially eligible and retrieved for full
review. After detailed review, 7 of these articles were
excluded for the following reasons: 4 utilized cross-
over designs, 1 was retrospective, 1 did not meet
our study inclusion criteria for outcome measures,and 1 was a duplicate publication of data already cap-
tured by our review. One article was identified by
personal communication. Subsequently, 28 articles
met our inclusion criteria and were included in the
systematic review (Figure 1). There were no discrep-
ancies between the 2 reviewers with regard to studies
for inclusion.
Study Demographics
The 28 articles reported on a total of 29 studies; 1
article reported the results of 2 studies [27]. There
were 22 single-center and 7 multi center trials, with
18 trials exclusively including subjects with hemato-
logic malignancies (Table 2). The most common indi-
cation for autologous transplantation was NHL (19
studies), followed by MM (17 studies), and Hodgkin
lymphoma ([HL] 11 studies). Eleven studies included
patients undergoing transplantation for both hemato-
logic malignancies and solid tumors.
Most studies included few participants; the largest
study involved 302 subjects (mean, 74.9; SD, 70.8;
range, 15-302). The mean age of study subjects was
46 years (SD, 9.3; range, 24.5-60).
Characteristics of HSC Mobilization Strategy
The HSC mobilization strategies evaluated are
summarized in Table 3. Two studies exclusively in-
cluded patients with newly diagnosed disease undergo-
ing autologous transplantation as consolidative
therapy after an initial response [28,29]. Ten studies
included only patients undergoing transplantation for
Table 2. Study Demographics
Study, Country Disease Sites Centers
No. of Patients Median Age
Gender,
% Female
Gp1 Gp2 Gp1 Gp2 Gp1 Gp2
Cyclophosphamide Plus Growth Factor
Ahn et al. [28], South Korea NHL, breast M 12 15 40 44.5 58.3 53.3
Demuynck et al. [33], Belgium MM S 11 11 50 52 36.3 81.8
Facon et al. [43], France, Spain, Belgium MM M 55 47 60 59 35 49
Gazitt et al. [44], USAa NHL S 10/12b 13 52/55b 46 20/9.1b 15.3
Martinez et al. [47], Spain MM S 8 7 48 48 50 42.9
Min et al. [51], South Korea NHL, MM, breast, Ewing’s sarcoma S 15 15 40 39 60 60
Narayanasami et al. [50], USA NHL, HL S 23 24 41 46 48 29
Pavone et al. [18], Italy NHL S 38 34 37a 35a 60.5 52.9
Quittet et al. A [27], France NHL, HL, MM, CLL, breast, testicular, ovarian S 31 29 51 54 47 45
Quittet et al. B [27], France NHL, HL, MM, CLL, breast, testicular, ovarian S 30 30 57 53 33 47
Vela-Ojeda et al. [48], USA MM, NHL, HL S 28 28 32 35.5 28.6 28.6
Growth Factor
Ataergin et al. [30], Turkey Heme, solid S 20 20 24.5 33 30 30
DiPersio et al. [41], USA MM M 148 154 58.2 58.4 32.4 30.5
DiPersio et al. [42], USA NHL M 150 148 56 59 33.3 31.1
Spitzer et al. [36], USA NHL, HL, MM, breast, germ cell/testicular,
ovarian
S 24 26 43 48 75 80.8
Stiff et al. [37], USA NHL, HL S 51 56 42 47.5 31 43
Weisdorf et al. [53], USA NHL, HL S 16 15 47 46 56 46.7
Combination/Non–Cyclophosphamide-Based Chemotherapy with Growth Factor
Andre et al. [39], Belgium NHL, HL, MM, breast M 62 66 49 46 75.8 83.3
Arora et al. [40], USA MM S 37 35 52.5 52.4 46 40
Copelan et al. [31], USA NHL S 28 27 54 47 37.3 40.7
Demirer et al. [32], Turkey L, MM, breast, testicular S 25 25 39 40 40 52
Hohaus et al. [34], Germany HL S 14 12 30.5 32 28.6 66.7
Hart et al. [29], Germany MM S 14 12 58a 61a 50 58
Kim et al. [45], South Korea MM, NHL S 20 20 52 55 30 35
Kopf et al. [46], Italya NHL, HL, MM, breast, germ cell,
osteosarcoma, other
S 36/29b 38 35/36b 43 58.3/51.7b 60.5
Ozcelik et al. [52], Turkey NHL, MM S 23 25 48 40.6 34.8 40
Shi et al. [35], China NHL, HL, germ cell S 15 15 29 21 40 7
Weaver et al. [49], USA NHL M 40 41 50 48 37 39
Weaver et al. [38], USAa L, MM, breast M 52/53b 51 46/48b 50 85/81b 84
Gp1 indicates comparator 1; Gp2, comparator 2; NHL, non-Hodgkin lymphoma; M, multicenter; MM, multiple myeloma; S, single center; HL, Hodgkin
lymphoma; CLL, chronic lymphocytic leukemia; Heme, hematologic malignancies; solid, solid malignancies; L, lymphoma.
aMean age.
bStudies with 3 arms; data for 2 experimental arms separated by forward slash.
1194 Biol Blood Marrow Transplant 18:1191-1203, 2012D. Sheppard et al.chemotherapy-sensitive relapsed disease [18,30-38].
Eleven studies included both categories of patients
[39-49], 1 study included relapsed or refractory disease
[50] and in 5 studies, this was unclear [27,51-53].
Studies varied with respect to the number of prior
treatment regimens patients had received (range, 0-5).
Included studies were grouped into 3 broad categories
based on the mobilization strategy (Table 4): (1)
cyclophosphamide with growth factor, (2) growth
factor(s) or (3) combination chemotherapy or non-
cyclophosphamide-based combination chemotherapy
plus growth factor.
Cyclophosphamide with Growth Factor
Strategy
Eleven studies used cyclophosphamide in combi-
nation with at least 1 growth factor as a comparator.
One study compared high-(4 g/m2) vs low-dose (1.5
g/m2) cyclophosphamide in combination with lenog-
rastim [28]. Three articles (4 studies) reported on com-
parisons between filgrastim and molgramostim: (1)Demuynck et al. [33] compared filgrastim and molgra-
mostim, each at 10 mcg/kg/day, in combination with
cyclophosphamide 4 g/m2, (2) in a 3-arm study, Gazitt
et al. [44] compared molgramostim 250mcg/day, mol-
gramostim 250 mcg/day for 7 days followed by filgras-
tim 10 mcg/kg/day, and filgrastim alone 10 mcg/kg/
day, each in combination with cyclophosphamide
3 g/m2, and (3) in a publication, Quittet et al. [27] re-
ported the results of 2 concurrent trials: study A com-
pared molgramostim 5 mcg/kg/day plus filgrastim
5 mcg/kg/day to filgrastim 5 mcg/kg/day, and study
B compared molgramostim 2.5 mcg/kg/day plus fil-
grastim 2.5 mcg/kg/day to filgrastim 5 mcg/kg/day,
each with cyclophosphamide. One trial studied the ad-
dition of ancestim 20 mcg/kg/day to a regimen of cy-
clophosphamide 4 g/m2 plus filgrastim 5 mcg/kg/day
[43], 1 trial compared cyclophosphamide 4 g/m2 with
and without the addition of molgramostim 5 mcg/
kg/day [47], and 1 examined early (day 2) vs late (day
8) addition of molgramostim 5 mcg/kg/day to cyclo-
phosphamide [51]. Two studies compared a different
Table 3. Characteristics of HSC Mobilization Strategy
Study
HSCT for
Initial/Salvage
Therapy
Median No.
of Prior Chemo
Regimens
Interventions
Gp1 Gp2
Cyclophosphamide with Growth Factor
Ahn et al. [28] Yes/no 1 CY 1.5 g/m2 + lenograstim 250 mcg/day CY 4 g/m2 + lenograstim 250 mcg/day
Demuynck et al. [33] No/yes NS CY 4 g/m2 + molgramostim 10 mcg/kg/day CY 4 g/m2 + filgrastim 10 mcg/kg/day
Facon et al. [43] Yes/yes NS CY 4 g/m2 + filgrastim 5 mcg/kg/day +
ancestim 20 mcg/kg/day
CY 4 g/m2 + filgrastim 5 mcg/kg/day
Gazitt et al. [44]a Yes/yes $1 CY 3 g/m2+ molgramostim 250 mcg/m2
Gp3: CY 3 g/m2+ molgramostim 250 mcg/m2
followed by filgrastim 10 mcg/kg/day
CY 3 g/m2+ filgrastim 10 mcg/kg/day
Martinez et al. [47] Yes/yes $1 CY 4 g/m2 + molgramostim 5 mcg/kg/day CY 4 g/m2
Min et al. [51] NS/yes NS CY 4 g/m2 + filgrastim 250 mcg/day (late) CY 4 g/m2 + filgrastim 250 mcg/day (early)
Narayanasami et al. [50] No/yes NS Filgrastim 10 mcg/kg/day CY 5 g/m2 + filgrastim 10 mcg/kg/day
Pavone et al. [18] No/yes NS DHAP + filgrastim 5 mcg/kg/day CY + filgrastim 5 mcg/kg/day
Quittet et al. A [27] NS/yes NS CY 4 g/m2 + molgramostim 5 mcg/kg/day +
filgrastim 5 mcg/kg/day
CY 4 g/m2 + filgrastim 5 mcg/kg/day
Quittet et al. B [27] NS/yes NS CY 4 g/m2 + molgramostim 2.5 mcg/kg/day +
filgrastim 2.5 mcg/kg/day
CY 4 g/m2 + filgrastim 5 mcg/kg/day
Vela-Ojeda et al. [48] Yes/yes $1 IFO + molgramostim 5 mcg/kg/day CY 4 g/m2+ molgramostim 5 mcg/kg/day
Growth Factor
Ataergin et al. [30] No/yes NS Lenograstim 7.5 mcg/kg/day Filgrastim 10 mcg/kg/day
DiPersio et al. [41] Yes/yes 1-2 Plerixafor + filgrastim 10 mcg/kg/day Filgrastim 10 mcg/kg/day
DiPersio et al. [42] Yes/yes 1-2 Plerixafor + filgrastim 10 mcg/kg/day Filgrastim 10 mcg/kg/day
Spitzer et al. [36] No/yes NS Molgramostim 5 mcg/kg/day + filgrastim
10 mcg/kg/day
Filgrastim 10 mcg/kg/day
Stiff et al. [37] No/yes $1 Filgrastim 10 mcg/kg/day Filgrastim 10 mcg/kg/day + ancestim
20 mcg/kg/day
Weisdorf et al. [53] NS/yes NS Molgramostim 250 mcg/m2/day Filgrastim 250 mcg/m2/day
Combination/Non–Cyclophosphamide-Based Chemotherapy with Growth Factor
Andre et al. [39] Yes/yes 1-2 Chemo + filgrastim 10 mcg/kg/day Chemo + filgrastim 5 mcg/kg/day
Arora et al. [40] Yes/yes $1 CMD + molgramostim 250 mcg/m2/day CMD + filgrastim 250 mcg/m2/day
Copelan et al. [31] No/yes 2-3 R + VP-16 + filgrastim 10 mcg/kg/day VP-16 + filgrastim 10 mcg/kg/day
Demirer et al. [32] No/yes 1-2 Chemo + filgrastim 16 mcg/kg/day Chemo + filgrastim 8 mcg/kg/day
Hohaus et al. [34] No/yes 2-3 DexaBEAM + molgramostim 5 mcg/kg/day DexaBEAM + filgrastim 5 mcg/kg/day
Hart et al. [29] Yes/no 1 IEE + filgrastim 5 mcg/kg twice a day + EPO IEE + filgrastim 5 mcg/kg twice a day
Kim et al. [45] Yes/yes $1 Chemo + lenograstim 5 mcg/kg twice a day Chemo + lenograstim 10 mcg/kg/day
Kopf et al. [46]a Yes/yes 1 Chemo + lenograstim 5 mcg/kg/day
Exp2: Chemo + molgramostim 5 mcg/kg/day
Chemo + filgrastim 5 mcg/kg/day
Ozcelik et al. [52] NS/yes 2 CE + filgrastim 10 mcg/kg/day (late) CE + filgrastim 10 mcg/kg/day (early)
Shi et al. [35] No/yes 5 VP-16 1,000 mg/m2 + filgrastim 300 mcg/day VP-16 1,500 mg/m2 + filgrastim 300 mcg/day
Weaver et al. [49] Yes/yes $1 CIS + CE + filgrastim 6 mcg/kg/day CE + filgrastim 6 mcg/kg/day
Weaver et al. [38]a No/yes NS Chemo + sargramostim 250 mcg/m2/day
Gp3: chemo + sargramostim 250 mcg/m2/day
followed by filgrastim 6 mcg/kg/day
Chemo + filgrastim 6 mcg/kg/day
HSC indicates hematopoietic stem cell; HSCT, hematopoietic stem cell transplantation; Gp1, comparator 1; Gp2, comparator 2; Gp3, Comparator 3;
CY, cyclophosphamide; NS, not stated; Exp2, XXX; DHAP, cisplatin, cytosine arabinoside, dexamethasone; IFO, ifosfamide; CMD, cyclophosphamide,
mitoxantrone, dexamethasone; R, rituximab; VP-16, etoposide; DexaBEAM, dexamethasone, carmustine, etoposide, cytarabine, melphalan; IEE, ifosfa-
mide, epirubicin, etoposide; EPO, erythropoietin; CE, cyclophosphamide, etoposide; CIS, cisplatin.
aStudies with 3 arms; data for 2 experimental arms separated by forward slash.
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Pavone et al. [18] compared DHAP for mobilization
in patients with NHL, and (2) Vela-Ojeda et al. [48]
used ifosfamide in patients with lymphoma or MM.
These studies used chemotherapy in combination
with filgrastim and molgramostim 5 mcg/kg/day,
respectively. Finally, 1 study compared filgrastim
10 mcg/kg/day with and without cyclophosphamide
5g/m2 [50].
Growth Factor or Non–Chemotherapy-Based
Mobilization Strategy
Six studies evaluated a mobilization strategy in-
volving one or more growth factors without chemo-
therapy. Three studies compared growth factors: (1)
Ataergin et al. [30] compared filgrastim 10 mcg/kg/day to lenograstim 7.5 mcg/kg/day, (2) Spitzer et al.
[36] compared filgrastim 10 mcg/kg/day to molgra-
mostim 5 mcg/kg/day in combination with filgrastim
10 mcg/kg/day, and (3) Weisdorf et al. [53] compared
filgrastim tomolgramostim, both at a dose of 250mcg/
m2/day. One study investigated the addition of ances-
tim 20 mcg/kg/day to filgrastim [37], and 2 articles
reported on the addition of plerixafor to filgrastim
[41,42].
Combination Chemotherapy or Non–
Cyclophosphamide-Based Chemotherapy with
Growth Factor Strategy
Twelve studies compared combination chemo-
therapy or non–cyclophosphamide-based chemother-
apy plus one or more growth factors. Of these,
Table 4. Summary of HSC Mobilization Strategy Comparisons
Study Comparison
HSC Mobilization Strategy
CY + Growth Factor Growth Factor Alone
Combination/Non–CY-based
Chemotherapy + Growth Factor
Growth factor type Demuynck et al. [33]
Gazitt et al. [44]
Quittet et al. [27]
Ataergin et al. [30]
Spitzer et al. [36]
Weisdorf et al. [53]
Arora et al. [40]
Hohaus et al. [34]
Kopf et al. [46]
Weaver et al. [38]
Growth factor dose Andre et al. [39]
Demirer et al. [32]
Growth factor timing Min et al. [51] Ozcelik et al. [52]
Growth factor single or divided dose Kim et al. [45]
Addition of plerixafor DiPersio et al. [41]
DiPersio et al. [42]
Addition of rituximab Copelan et al. [31]
Addition of ancestim Facon et al. [43] Stiff et al. [37]
Addition of erythropoietin Hart et al. [29]
Chemo +/2growth factor Martinez et al. [47]
Growth factor +/2chemo Narayanasami et al. [50]
Varied chemo dose Ahn et al. [28]
Varied chemo regimen Pavone et al. [18]
Vela-Ojeda et al. [48]
Shi et al. [35]
Weaver et al. [49]
HSC indicates hematopoietic stem cell; CY, cyclophosphamide.
1196 Biol Blood Marrow Transplant 18:1191-1203, 2012D. Sheppard et al.2 studies compared growth factor dose: (1) Andre et al.
[39] compared filgrastim at 5 and 10 mcg/kg/day, and
(2) Demirer et al. [32] compared doses of 8 and 16
mcg/kg/day. Four studies compared growth factors:
(1) filgrastim vs molgramostim, each at 250 mcg/m2/
day [40], (2) filgrastim vs molgramostim, each at 5
mcg/kg/day [34], (3) filgrastim vs molgramostim vs
lenograstim, each at 5 mcg/kg/day [46], and (4) filgras-
tim 6 mcg/kg/day vs sargramostim 250 mcg/m2/day vs
sargramostim 250 mcg/m2/day for 5 days followed by
filgrastim 6 mcg/kg/day [38]. One study investigated
the addition of rituximab to a combination of etopo-
side and filgrastim 10 mcg/kg/day [31], one investi-
gated the addition of erythropoietin to a strategy of
combination chemotherapy plus filgrastim 5 mcg/kg
bid [29], one studied single-dose or divided-dose le-
nograstim (10 mcg/kg/day vs 5 mcg/kg twice a day)
[45], and one studied early (day 4) vs late (day 7) com-
mencement of filgrastim [52]. Two studies compared
chemotherapy regimens: Shi et al. [35] compared 2 dif-
ferent etoposide doses (1,000 vs 1,500 mg/m2) in com-
bination with filgrastim 300 mcg/day, and Weaver
et al. [49] studied the addition of cisplatin to a regimen
involving cyclophosphamide, etoposide, and filgrastim
6 mcg/kg/day.
Quality of Studies
Items included in the quality assessment are de-
scribed in Table 5. Three (11%) studies were assigned
a Jadad score of at least 3 [31,41,42], with only 2 studies
clearly describing allocation concealment [42,47] and 2
describing an appropriate method of randomization
[31,46]. Three studies were stated to be double blind
[34,41,42], although none described the process of
blinding. Fourteen articles discussed withdrawals or
dropouts. Seven articles (25%) clearly stated theduration of patient follow-up [40-44,50,53], and in
3 (11%), it was stated that the analysis was by
intention to treat [41-43].Efficacy of Hematopoietic Stem Cell
Mobilization Strategies
Primary outcome: CD341 cell yield
Of the studies that evaluated a cyclophosphamide
with growth factor strategy, 3 used interventions that
resulted in a statistically significant improvement in
CD341 cell yield (Table 6). In the study by Facon
et al. [43], the addition of ancestim resulted in amedian
CD341 cell yield of 12.4  106/kg compared with
8.2  106/kg for cyclophosphamide plus filgrastim
without ancestim (P 5 .007). In the Martinez et al.
[47] study, the addition of growth factor (molgramos-
tim) to cyclophosphamide resulted in a significant im-
provement in median CD341 cell yield (1.4 vs 0.5 
106/kg; P 5 .0165). Narayanasami et al. [50] reported
CD341 cell yield was improved with cyclophospha-
mide combined with filgrastim over filgrastim alone
(7.2 vs 2.5  106/kg; P 5 .004).
Of the studies that used a non-chemotherapy
mobilization strategy, significant improvement in
CD341 cell yield was achieved with plerixafor in com-
bination with G-CSF in patients with MM (11.0 vs
6.2  106/kg; P\ .001) [41] or NHL (5.69 vs 1.98 
106/kg; P\ .01) [42].
In the category of non–cyclophosphamide-based
chemotherapy with growth factor, 2 studies found sig-
nificantly improved CD341 cell yield with their inter-
ventions. In the Copelan et al. [31] study including
exclusively patients with NHL, rituximab improved
the yield (9.9 vs 5.6  106/kg; P 5 .021). Doubling
the dose of filgrastim improved the CD341 cell yield
Table 5. Quality Assessment
Study
Jadad Scoring System Questionsa
1 2 3 4 5 6 7 Jadad score
Allocation
concealment? ITT analysis?
Cyclophosphamide with Growth Factor
Ahn et al. [28] + 2 2 2 2 2 2 1 2 2
Demuynck et al. [33] + 2 2 2 2 2 2 1 2 2
Facon et al. [43] + 2 2 2 2 2 + 2 2 +
Gazitt et al. [44] + 2 2 2 2 2 2 1 2 2
Martinez et al. [47] + 2 2 2 2 2 2 1 2 2
Min et al. [51] + 2 2 2 2 2 + 2 2 2
Narayanasami et al. [50] + 2 2 2 2 2 + 2 2 2
Pavone et al. [18] + 2 2 2 2 2 2 1 2 2
Quittet et al. A [27] + 2 2 2 2 2 2 1 2 2
Quittet et al. B [27] + 2 2 2 2 2 2 1 2 2
Vela-Ojeda et al. [48] + 2 2 2 2 2 2 1 2 2
Growth Factor Alone
Ataergin et al. [30] + 2 2 2 2 2 N/A N/A 2 N/A
DiPersio et al. [41] + 2 2 + 2 2 + 3 2 +
DiPersio et al. [42] + 2 2 + 2 2 + 3 + +
Spitzer et al. [36] + 2 2 2 2 2 2 1 2 2
Stiff et al. [37] + 2 2 2 2 2 + 2 2 2
Weisdorf et al. [53] + 2 2 2 2 2 + 2 2 2
Combination/Non–Cyclophosphamide-Based Chemotherapy with Growth Factor
Andre et al. [39] + 2 2 2 2 2 + 2 2 2
Arora et al. [40] + 2 2 2 2 2 + 2 2 2
Copelan et al. [31] + + 2 2 2 2 + 3 2 2
Demirer et al. [32] + 2 2 2 2 2 N/A N/A 2 N/A
Hohaus et al. [34] + 2 2 + 2 2 2 2 2 2
Hart et al. [29] + 2 2 2 2 2 + 2 2 2
Kim et al. [45] + 2 2 2 2 2 2 1 2 2
Kopf et al. [46] + + 2 2 2 2 2 2 + 2
Ozcelik et al. [52] + 2 2 2 2 2 2 1 2 2
Shi et al. [35] + 2 2 2 2 2 + 2 2 2
Weaver et al. [49] + 2 2 2 2 2 + 2 2 2
Weaver et al. [38] + 2 2 2 2 2 + 2 2 2
ITT indicates intension to treat; +, yes; 2, no; N/A, not applicable.
aJadad scoring system questions: (1) Was the study described as randomized? (2) Was an appropriate randomization sequence described and used? (3)
Was an inappropriate method to generate the sequence of randomization used? (4) Was the study described as double blinded? (5) Was an appropriate
method for blinding used? (6) Was an inappropriate method for blinding used? (7) Were withdrawals and dropouts described?
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group of patients (8.2 vs 4.7  106/kg; P\ .0001).
Secondary outcomes
Three studies used interventions that resulted in
fewer aphereses required to reach the minimal HSC
target. In the Facon et al. [43] study, a median of 1
apheresis was required to collect a target of 5  106
CD341 cells/kg in the group that received ancestim,
vs 2 aphereses for the control group that received cyclo-
phosphamide with filgrastim only (P 5 .008). In the
Demirer et al. [32] study, patients who received the
higher dose of filgrastim required a median of 1 apher-
esis procedure, as compared with 2 in patients receiving
the lowerdose (P\.001) to achieve aminimumCD341
cell dose of 2.5 106/kg. In patients withMMreceiving
plerixafor as part of theirmobilization strategy to collect
an adequate graft for 2 transplantations, the median
number of aphereses to achieve a target of 6  106
CD341 cells/kg decreased from 4 to 1 (P\ .001) [41].
Sixteen articles reported the proportion of patients
failing to collect the minimum number of HSCsrequired to proceed to transplantation as defined
by the study protocol [18,27,29-31,37,38,40,41,43-
45,47,48,52].
Four of these reported the proportion that failed out
of the entire study population only [18,27,40,45], and
the other 12 reported the proportion for the individual
study groups. None of the studies reported statistically
significant differences between groups, either because
none was found [18,29,31,35,43,44,47,52] or because
significance testing was not done/reported.
Twelve studies reported on the proportion of pa-
tients who ultimately proceeded to transplantation
[28,31,35,37,40-42,45-47,49,51]. The only significant
result was reported in the DiPersio study [42] compar-
ing plerixafor combined with filgrastim to filgrastim
alone for HSC mobilization in patients with NHL.
In this study, 135 of 150 patients receiving plerixafor
proceeded to transplantation after initial mobilization,
compared with 82 of 148 patients receiving filgrastim
alone (P\ .001). In this study, patients failing to col-
lect at least 0.8 106 CD341 cells/kg after 2 apheresis
days or at least 2 106/kg in up to 4 apheresis days had
Table 6. HSC Mobilization Efficacy
Study
Median CD34+ Cell
Yield ( 106/kg)
Median No.
Aphereses
Proportion Failing to
Mobilize (Number, Percentage)
Gp1 Gp2 Gp1 Gp2 Gp1 Gp2
Cyclophosphamide with Growth Factor
Ahn et al. [28] 9.9 22.4 3 2.5 NS NS
Demuynck et al. [33] 23.7 12.7 NS NS NS NS
Facon et al. [43] 12.4b 8.2b 1b 2b 8/55, 14.5% 9/47, 19.1%
Gazitt et al. [44]a NS/NS NS 2/1 3 4/10, 40%/5/12, 41.7% 3/13, 23%
Martinez et al. [47] 1.4b 0.5b 6.4c 7.2c 1/8, 12.5% 1/7, 14.3%
Min et al. [51] 6.8 8.5 3.5 4 NS NS
Narayanasami et al. [50] 2.5b 7.2b ND ND NS NS
Pavone et al. [18] 5.9 7.1 2 2 5/38, 13.2% 4/34, 11.8%
Quittet et al. A [27] 18.3 9.0 2 2 4/56, 7.1%d 4/56, 7.1%d
Quittet et al. B [27] 15.9 8.1 2 2 3/53, 5.7%d 3/53, 5.7%d
Vela-Ojeda et al. [48] 3.1 5.3 3 3 4/28, 14.3% 3/28, 10.7%
Growth Factor Alone
Ataergin et al. [30] 2.0 3.2 2 1 1/20, 5% 1/20, 5%
DiPersio et al. [41] 11.0b 6.2b 1b 4b 0/148, 0% 7/154, 4.5%
DiPersio et al. [42] 5.7b 2.0b NS NS NS NS
Spitzer et al. [36] 13.3 21.5 NS NS NS NS
Stiff et al. [37] 3.6 2.4 NS NS 12/46, 26% 9/55, 16.4%
Weisdorf et al. [53] NS NS NS NS NS NS
Combination/Non–Cyclophosphamide-Based Chemotherapy Regimens with Growth Factor
Andre et al. [39] 12.0 7.2 2 2 NS NS
Arora et al. [40] 12.8 16.4 NS NS 7/72, 9.7%d 7/72, 9.7%d
Copelan et al. [31] 9.9b 5.6b 3 4 1/28, 3.6% 4/27, 14.8%
Demirer et al. [32] 8.2b 4.7b 1b 2b NS NS
Hohaus et al. [34] 5.6 7.6 NS NS NS NS
Hart et al. [29] 15.4 12.6 1.3 1.8 0/14, 0% 2/12, 16.7%
Kim et al. [45] 15.8 19.4 1 1 0/40, 0%d 0/40, 0%d
Kopf et al. [46]a 5.8/4.0 8.4 1/1 1 NS/NS NS
Ozcelik et al. [52] 10.8 10.5 1 1 3/23, 13% 4/25, 16%
Shi et al. [35] 27.3 36.0 3 3 0/30, 0%d 0/30, 0%d
Weaver et al. [49] 8.5 11.1 NS NS NS NS
Weaver et al. [38]a 5.4/10.5 12.0 3/2 2 4/49, 8.2%/1/52, 1.9% 2/49, 4.1%
HSC indicates hematopoietic stem cell; Gp1, comparator 1; Gp2, comparator 2; NS, not stated; ND, no difference.
aStudies with 3 arms; data for 2 experimental arms separated by forward slash.
bStatistically significant difference.
cMean (rather than median) calculated.
dResult provided for the study cohort combined.
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filgrastim. Of the 10 patients in the plerixafor arm
and the 52 patients in the filgrastim-alone arm eligible
for rescue, 4 (40%) and 33 (64%), respectively,
achieved a CD341 cell count of at least 2  106/kg
in#4 aphereses. Fifty-two of these patients (84%) pro-
ceeded to transplantation.
The majority of studies (83%) defined neutrophil
recovery post autologous HSCT as a neutrophil count
of at least 0.5 109/L for 1 to 3 days. Platelet recovery
was defined as a platelet count of 20 109/L in 68% of
studies (Table 7). In the group of studies that used a cy-
clophosphamide with growth factor strategy, time to
neutrophil recovery was improved with filgrastim
over molgramostim (11 vs 15 days; P \ .001) [41]
and with cyclophosphamide over ifosfamide (13 vs 16
days; P\ .02) [48]. Similarly, in patients that under-
went mobilization with growth factor alone, neutro-
phil recovery was faster with filgrastim compared
with molgramostim (13 vs 15 days; P 5 .01) [53]. In
patients receiving combination chemotherapy or
non–cyclophosphamide-based chemotherapy, time toneutrophil recovery was shorter with a higher dose of
filgrastim (9 vs 12 days for 16 vs 8 mcg/kg/day; P\
.001) [32] and without the addition of cisplatin (13 vs
15 days; P\ .0001) [49]. In the three-arm study com-
paring filgrastim to sargramostim to both sequentially,
neutrophil recovery was more rapid with a filgrastim-
containing regimen (11 days with filgrastim vs 14
days with sargramostim; P\ .0001 and 12 days with
both given sequentially; P\ .001) [38].
Platelet recovery was faster with cyclophospha-
mide plus filgrastim compared to DHAP plus filgras-
tim (10 vs 13 days; P 5 .022) [18]. In a growth
factor-alone strategy, filgrastim was associated with
more rapid platelet recovery than molgramostim (17
vs 28; P 5 .04) [53]. In a non–cyclophosphamide-
based chemotherapy with growth factor strategy, the
addition of cisplatin resulted in a delayed time to plate-
let recovery (14 vs 13 days; P 5 .009) [49].
Safety
Limited safety data were reported in the reviewed
studies. The most commonly reported adverse event
Table 7. Neutrophil and Platelet Recovery
Study
Neutrophil
Recovery,
Median Days
Platelet
Recovery,
Median Days
Gp1 Gp2 Gp1 Gp2
Cyclophosphamide with Growth Factor
Ahn et al. [28] 11 9.5 11 8
Demuynck et al. [33] 15b 11b NS NS
Facon et al. [43] 10 10 9 10
Gazitt et al. [44]a 10/11 11 11/11 11
Martinez et al. [47] 13.3 17.2 11.6 13.4
Min et al. [51] 11 11 19 16
Narayanasami et al. [50] 11 11 14 13
Pavone et al. [18] 9 10 13b 10b
Quittet et al. A [27] 11 11 15 15
Quittet et al. B [27] 11 11 15 15
Vela-Ojeda et al. [48] 16b 13b 17 15
Growth Factor Alone
Ataergin et al. [30] 11 10 12 11
DiPersio et al. [41] 11 11 18 18
DiPersio et al. [42] 10 10 20 20
Spitzer et al. [36] 18 21 16 16
Stiff et al. [37] 10 10 12 12
Weisdorf et al. [53] 15b 13b 28b 17b
Combination/Non–Cyclophosphamide-Based Chemotherapy
Regimens with Growth Factor
Andre et al. [39] 8 8 9 9
Arora et al. [40] 10 10 11 11
Copelan et al. [31] 10 10 16 17
Demirer et al. [32] 9b 12b 12 13
Hohaus et al. [34] 13 11.5 NS NS
Hart et al. [29] 10.7 10.9 ND ND
Kim et al. [45] 10 10 11 12
Kopf et al. [51]a NS/NS NS NS/NS NS
Ozcelik et al. [52] 13.6 12.6 NS NS
Shi et al. [35] 10 10 12 12
Weaver et al. [49] 15b 13b 14b 13b
Weaver et al. [38]a 14b/12b 11b ND/ND ND
Gp1 indicates comparator 1; Gp2, comparator 2; NS, not stated; ND, no
difference.
aStudies with 3 arms; data for 2 experimental arms separated by forward
slash.
bStatistically significant difference.
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studies in which chemotherapy formed part of the
mobilization strategy. The percentage of patients de-
veloping this complication varied from 2% to 100%.
The proportion of patients requiring hospital admis-
sion was documented in 3 studies, all of which used
a combination chemotherapy-plus-growth factor strat-
egy [38,49,50]. In studies where chemotherapy was
used, the percentage of patients requiring hospital
admission ranged from 20% to 48% [38,49,54].
The number of patients requiring admission to an
intensive care unit was not reported in any of the
studies. Mortality at 100 days was reported in 2
studies [31,43]. In the Copelan publication [31], 1
death was observed in each of the groups receiving
etoposide and filgrastim with and without rituximab.
In the Facon [43] study of the addition of ancestim to
cyclophosphamide and filgrastim, no deaths were
observed.DISCUSSION
Autologous HSCT is an important treatment mo-
dality in the management of patients with hematologic
malignancies. Requisite for auto-HSCT is the collec-
tion of an adequate number of HSCs. Our systematic
review identified 29 RCTs of HSC mobilization strat-
egies before autologous transplantation for hemato-
logic malignancies.
Although differences were reported with the vari-
ous approaches, and some strategies were superior
with regard to the reported outcomes, all approaches
were successful in mobilizing adequate numbers of
CD341 cells in the majority of patients. In general,
more CD341 cells were collected by strategies using
higher doses of G-CSF, by adding chemotherapy to
G-CSF, or by combining G-CSF with either ancestim
or the novel agent plerixafor. In addition, some strate-
gies decreased the number of aphereses required to
reach a target CD341 cell dose. These gains came
with the issues of tolerability (allergic potential of
ancestim), the risk of febrile neutropenia and hospital-
ization, and potential delay of collection with chemo-
therapy or up front higher costs of the novel agent
plerixafor. Unfortunately, the reported studies
provided little information regarding these ancillary
issues.
Despite multiple attempts to improve HSC yield,
in 5% to 46% [54,55] of patients, there is failure to
collect adequate HSCs. Predictors of mobilization
failure include older age [56], previous chemotherapy
[57,58], exposure to lenalidomide [59], and extensive
bone marrow involvement by malignancy. However,
there is presently no reliable way to determine which
patients are most likely to fail mobilization and, hence,
could potentially benefit from a novel mobilization
strategy. The Italian Group for Stem Cell Transplan-
tation (GITMO) recently proposed a set of clinical cri-
teria defining patients predicted to be poor mobilizers,
although this has not yet been validated [60]. Others
have reported on the utility of CD341 cell counts to
determine which patients might benefit from the pre-
emptive addition of plerixafor [61,62].
In 2 recent phase III studies in patients with MM
[41] and lymphoma [42], plerixafor combined with fil-
grastim resulted in a significantly higher proportion of
patients achieving the minimum CD341 cell yield
than filgrastim alone. Moreover, patients failing initial
collection could be effectively rescued with plerixafor
and filgrastim, such that 100% of patients with MM,
and 84% of patients with lymphoma could proceed
to transplantation. However, it is notable that in
both these studies, there was higher than anticipated
primary mobilization failure in the control (filgrastim
alone) arm. The Food & Drug Administration-
approved filgrastim dose of 10 mcg/kg may have
been suboptimal, particularly if these results are to
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factors for mobilization failure.
Beyond the data previously cited, published experi-
ence with the newest agent, plerixafor, is limited, and
many groups are exploring how best to use it in mobi-
lization. One strategy is to use plerixafor pre-emptively
for patients deemed to be at high risk for mobilization
failure based on a pre mobilization risk profile, pre
collection peripheral blood CD341 cell count, or
day 1 CD341 cell yield. A recent study used recursive
partitioning analysis to define a day 1 CD341 cell
yield of #0.7  106/kg that predicts mobilization fail-
ure [61]. Abhyankar et al. [62] described a pre-emptive
or risk-based algorithm for the use of plerixafor. Pa-
tients were identified as being at risk for mobilization
failure based on a low CD341 cell yield on the first
day of collection. Of 159 patients undergoing HSC
collection using this approach, 151 (95%) provided
adequate collections with one mobilization attempt.
Costa et al. [63] developed a cost-based algorithm
based on CD341 cell count on the fourth day of growth
factor and the targetCD341 cell count todecidewhether
to add plerixafor. The mobilization failure rate was
reduced to 2% from22% in a historical cohortmobilized
with cyclophosphamide and growth factor. Others have
attempted to create similar algorithms based on cost-
effectiveness analyses [64-66]. Recently, plerixafor has
been studied in the context of mobilization with
chemotherapy plus growth factor [67,68]. Attolico et al.
[68] reported on the safety and efficacy of plerixafor ‘‘res-
cue’’ in predicted poor mobilizers undergoing chemo-
therapy plus growth factor-based mobilization.
HSC yield is not the only consideration when
choosing an optimal mobilization strategy. Mobiliza-
tion chemotherapy is commonly used to purge the
stem cell product in vivo from circulating malignant
cells or as part of salvage chemotherapy despite the
lack of clear benefit. In a study by Gazitt et al. [69],
lymphoma cell mobilization was identified in 35% of
patients tested. Circulating lymphoma cells were
more prevalent in patients who failed to mobilize in
2 days than in those who mobilized successfully. How-
ever, as recently reviewed by DiPersio et al. [70], the
relevance of clonal B cells collected along with periph-
eral blood HSCs remains uncertain. The technique
used to collect the stem cells is also important. For ex-
ample, large volume leukapheresis has been associated
with improved yields but increased adverse effects in-
cluding thrombocytopenia and muscle and bone pain
[71]. Finally, there is also a growing body of literature
suggesting that higher numbers of lymphocytes in the
stem cell product and specifically natural killer cell
content, lead to improved survival posttransplantation
[72]. These issues were not adjusted for nor addressed
in the reviewed studies.
This review has several limitations. Most of the
studies reviewed were small with limited power todetect differences, and most were of modest methodo-
logical quality. The study populations varied in terms
of diseases, number and type of prior treatments, and
interventions studied. Additionally, the summary sta-
tistics varied between studies. These factors precluded
a meaningful meta-analysis and make it difficult to
draw definitive conclusions from these data.
How then to apply these data? If all approaches are
reasonable, other criteria must be considered when de-
ciding on a mobilization strategy for a group of pa-
tients or a program. The choice should reflect the
unique circumstances of the program and the health
care system in which they function. Identifying which
issue or issues limit the efficiency of graft collection
will enable the program to identify the approach that
best accommodates or addresses the limitations.
Unfortunately, the solutionmay not necessarily re-
flect optimal medical practice but may reflect resource
limitations, budgetary or cost allocation issues, lack of
access to particular drugs, or other issues unique to
a program or patient. For example, if drug acquisition
cost is limiting, and the program does not have overall
budget control that would allow them to recoup the
savings associated with fewer aphereses or the avoid-
ance of febrile neutropenia, then plerixafor may not
be an option for that program—at least not until
broader arguments can effectively be developed. If ac-
cess to transplantation beds is limiting, the center
may wish to use chemotherapy as part of the mobiliza-
tion strategy with the hopes of providing some disease
control while waiting to start the transplantation con-
ditioning. This may be reasonable, although chemo-
therapy with mobilization has not been shown to
decrease tumor contamination of the graft or result in
improved survival if patients proceed directly to trans-
plantation [50,73]. In another setting, restrictions put
on the use of specific agents by licensing bodies or
third-party payers may restrict innovative use of novel
agents or application of them as part of front-line
approaches. For example, in Canada, the special
access program, pending plerixafor’s approval, did not
allow the addition of plerixafor during mobilization
for patients identified as failing mobilization based on
a low peripheral blood CD34 count after 4 or 5 days
of G-CSF. On a more positive note, if access to
apheresis slots is limiting but budget allows, the
introduction of plerixafor could facilitate reproducible
scheduling, and, as reported, fewer aphereses per
patient, easing this bottleneck for a program.
Other considerations may be difficult to quantify.
By enhancing CD341 cell yield, plerixafor was able
to rescue some patients with NHLwho failed to mobi-
lize an adequate graft. These patients then had the op-
portunity to undergo a potentially curative autologous
HSCT. The downstream benefit of this includes de-
creasing the number of patients receiving potentially
expensive but ineffective palliative therapy or a much
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with an allogeneic HSCT. How to best quantify these
tradeoffs in an objective manner should be the focus of
future studies.
Important questions remain. First, the value of
combining cyclophosphamide and growth factor over
growth factor alone has been shown in one, small, ran-
domized study in patients with lymphoma. The opti-
mal chemotherapy regimen has not been defined in
any patient population, and the benefit of adding
chemotherapy at all has not been studied in an RCT
involving patients with MM. Given the apparent lack
of benefit in terms of disease response [73], it is un-
known whether the potential benefit outweighs the
risks and cost associated with febrile neutropenia and
the need for hospital admission in a substantial propor-
tion of patients. Second, the optimal use of plerixafor
has yet to be defined. It is likely that a risk-adapted
approach will ultimately provide the greatest clinical
benefit, while remaining cost-effective. Third, the rel-
evance of tumor cell mobilization and the efficacy of
strategies to reduce it is unknown. Fourth, questions
relating to the effect on the graft composition remain
to be elucidated. Finally, there are several investiga-
tional agents showing benefit in animal models and
early clinical studies, including the VLA-4 antibody,
natalizumab [74], retinoic acid receptor-a agonists
[75], and thrombopoietin receptor agonists.
Currently, autologous stem cell graft mobilization
is carried out using a variety of approaches, mostly
with success. Existing RCT data demonstrating differ-
ences between various approaches do not provide ade-
quate healthcare systems data to informed choices,
leaving the decision on mobilization strategy to indi-
vidual programs based on local issues or historical
practices. As with the introduction of any new effective
tool, transplantation physicians will now have to
review their existing practices to determine whether
the availability of plerixafor has the potential to en-
hance patient care within the structure of their pro-
gram and healthcare system.ACKNOWLEDGMENTS
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